We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Phosphagen. | PSG | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 2.25 | 01:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 2.25 | 2.25 |
| Top Posts |
|---|
Posted at 20/10/2010 00:39 by rambutan2 Hi gavapentin, the potential for some fat returns perhaps... 19 October 2010 PHOSPHAGENICS ON TRACK TO COMMERCIALISE ANTI-FAT PEPTIDE USING TPM TECHNOLOGY Focus group studies to start this year Potential US$3 billion global market Cosmeceutical product sales expected early 2011 Phosphagenics Limited (ASX: POH) has today signed a licensing deal with Calzada Limited (ASX: CZD), formerly Metabolic Pharmaceuticals, to launch a cosmeceutical product containing Calzada's anti-obesity peptide known as AOD9604 in combination with the TPM delivery technology. The August 2010 Southern Cross Phosphagenics Report goes into some detail on the above. |
Posted at 17/7/2009 21:53 by newbi55 There are a number of threads on PSG (POH on ASX) on an Australian Investment Network at Worth a look to read other opinions (from an Australian Investors point of view)about this company and it's free to sign up. Can anyone tell me the best way to trade these shares from here in the UK? Recommend a broker perhaps. |
Posted at 11/10/2008 20:33 by jaydeee Hi All re the delisitng from AIM, I just emailed the company and they said the following. They are going to try and make an announcement on this as well, so hold tight and don't sell. "Briefly, members are able to continue to trade their securities in the UK up to 31 October and after normal settlement of those trades the DI and Certificated Registers will be closed and the securities cancelled. From the Company's principal Register of Members shares will be allotted to the members together with the personal Holder Identification Number ("HIN") which is the key to being able to trade the securities on the Australian Stock Exchange ("ASX"). The UK members may of their own volition transfer their securities to the principal Register of Members ahead of the 31 October close simply by obtaining from Computershare Investor Services PLC in Bristol a 'removal form'. " There will be no cost to the shareholder for doing this |
Posted at 16/5/2008 18:45 by donaferentes Last fund-raising was not available to AIM/UK investors. This company almost always ignores its London presence and is the one reason why my faith in it may not last. Their NOMAD needs to pull their finger out and advise them that UK investors are due equal consideration to the Ozzies home team. |
Posted at 16/5/2008 13:51 by ladybird1 Brave man, outsize, considering buying a few more!Selling a further 10% of the equity, at this price & for a pretty small amount, doesn't give a lot of confidence that there will be positive news in this calender year or early 2009. The Nestle deal going bad, for instance? Whatever, the contrast is stark between this rather shifty bit of fund raising from institutions & 'sophisticated investors' & the last fund raising which they felt able to make available to all holders (not easy in the UK admittedly, but the general principle of confidence was clear). They've been very quiet this time round. Why? - they're not usually shy at blowing the trumpet. The next update on progress will be of interest. |
Posted at 07/5/2008 07:48 by hopeless698 07 May 2008Company Announcement Phosphagenics Completes A$9.1 M Capital Raising Phosphagenics Limited ("Phosphagenics") (ASX: POH, AIM: PSG, OTCQX: PPGNY) today announced that it has raised A$9.1 m via a placement of approximately 60.6 million fully paid ordinary shares to leading overseas and domestic institutions, and other sophisticated investors, at 15 cents per share. It is expected that trading in the new shares on the Australian Stock Exchange will commence on or around 12 May 2008. Mr Harry Rosen, Phosphagenics' President & CEO said that the company was very pleased with the response from investors. "We are very pleased to receive this substantial support from our existing shareholders as we continue to focus on the discovery of new and cost-effective ways to enhance the bioavailability, delivery, efficacy and safety of proven pharmaceutical and nutraceutical products," Mr Rosen said. "The funds raised considerably strengthen the Company's financial position and together with government grants and other revenue will support Phosphagenics' research and development programs through to the end of calendar year 2009," he said. Attached for release to the market is an Appendix 3B notice together with a Section 708A notice. ENDS....... APPENDIX AND NOTES TO EDITORS About Phosphagenics Limited Phosphagenics is a Melbourne-based, globally driven biotechnology company focused on the discovery of new and cost effective ways to enhance the bioavailability, activity, safety and delivery of proven pharmaceutical and nutraceutical products. Phosphagenics' core technology is built around the science and application of phosphorylation, a process where the addition of a phosphate group has been found to enhance the bioavailability, efficacy and safety of existing pharmaceuticals and nutraceuticals, as well as to assist in the production of drug delivery platforms. |
Posted at 30/4/2008 07:24 by hopeless698 Pre-Clinical Trial ResultsRNS Number:4072T Phosphagenics Limited 30 April 2008 30 April 2008 Company Announcement Phosphagenics Reports Positive Pre-clinical Results for Targeted Delivery of Lidocaine - Company's TPM Drug Delivery Technology Demonstrates Substantial Increase in Lidocaine Penetration Compared to a Leading Marketed Product - Phosphagenics Limited ("Phosphagenics") (ASX: POH, AIM: PSG, OTCQX: PPGNY) today announced positive results of a pre-clinical study using TPM, the Company's patented drug deliver system, for the targeted delivery of lidocaine, demonstrating increased efficacy while restricting systemic exposure. A phase 1 human clinical trial is scheduled to commence in the third quarter of 2008. Study Design The study was designed to demonstrate the ability of TPM to deliver lidocaine (5%) to a targeted local site after a single topical application, while restricting systemic exposure. Lidocaine concentrations were measured in the skin at the site of application as well as in the underlying muscle and tissue. The studies were performed in parallel using a leading commercial form of lidocaine, Xylocaine(R) 5%, to assess the relative efficacy of the TPM/Lidocaine formulation. TPM/Lidocaine or Xylocaine(R) (20microgram) were applied to a 2x2 cm2 area of shaved skin on the thigh of the treatment, or control animals (n=10). Blood samples were taken at 0 (before application), 1, 2, 3, and 5 hours after application. Lidocaine concentrations were measured in the skin at the site of application as well as in the underlying muscle to determine the amount of lidocaine delivered to the local area of application. Plasma lidocaine concentration was quantified to evaluate systemic exposure. Study Results Phosphagenics' TPM/Lidocaine increased, by a statistically significant margin (p London Stock Exchange's Alternative Investment Market (PSG). An ADR - Level 1 program was established in the U.S. with The Bank of New York Mellon (PPGNY) for U.S. investors to trade in Phosphagenics' stock on the 'over-the-counter' market. In July 2007, this was upgraded to the International OTCQX, a new premium market tier in the U.S. for international exchange-listed companies, operated by Pink Sheets, LLC. For more information, please visit Phosphagenics' web site at www.phosphagenics.co Safe Harbor Statement This press release contains forward-looking statements based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialise, actual results could vary materially from the Phosphagenics' expectations and projections. Risks and uncertainties include general industry conditions and competition; economic conditions, such as interest rate and currency exchange rate fluctuations; technological advances and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; domestic and foreign health care reforms and governmental laws and regulations. Company Contact Details: U.S. Investor and Media Contacts: Esra Ogru Brian Ritchie Phosphagenics Limited Financial Dynamics Executive VP R&D +1 212 850 5683 +61 3 9605 5900 Mary McSwiggan Phosphagenics Limited Investor Relations Manager +61 3 9605 5907 |
Posted at 27/2/2008 10:40 by donaferentes As ever Australian accounts are designed to send yp to sleep before youu find out any material information.Another year of solid, if stately, progress. My guess is there will be another fund raising (which I assume will not be open to mere AIM shareholders, but restricted to the Australian master-race of investors). They have A$10m cash and a cash burn rate of about the same last year which may increase as they get nearer final trials and eventual release to the market of their excellent products. One to tuck away and forget for a couple more years when the rewards could be stupendous. |
Posted at 04/12/2007 18:42 by donaferentes Also note that under Market Cap section only ASX is mentioned. Someoe ought to write to their UK NOMAD and get them onside to keep half their investors informed better. Good operational company though for all that. But quite a way to go as page 23 shows, until US fully approves. |
Posted at 03/5/2007 09:22 by basketbob Phosphagenics Limited03 May 2007 Phosphagenics Limited AusIndustry offers Phosphagenics a Pharmaceuticals Partnerships Program (P3) grant of $3.2 million 03 May 2007 Melbourne, Australia, 03 May 2007: The Industry Minister, Hon Ian Macfarlane, announced today that Vital Health Sciences Pty Ltd, a wholly-owned subsidiary of Phosphagenics Limited (ASX: POH) (AIM: PSG) (ADR/OTC: PPGNY), has been offered a research grant under the AusIndustry Pharmaceuticals Partnerships Program (P3) of up to $3.2 million. P3 is a competitive government grant program aimed at increasing the amount of high quality pharmaceutical R&D activity in Australia. The P3 grant entitles Phosphagenics to funding of up to $3.2 million over two years starting from 01 July 2007 to support a number of its drug-development projects, dependent on the company meeting forecast R&D expenditure for the period. The funding will be used to further develop Phosphagenics' R&D portfolio, including the following: pre-clinical and clinical development of its TPM transdermal delivery technology and oral drug delivery technology for the treatment of diabetes, chronic pain management and other markets; and pre-clinical and clinical development of its lead compounds for the treatment of atherosclerosis/meta cancer (GTP-0805). Mr Harry Rosen, President and CEO of Phosphagenics, said 'Phosphagenics patented technologies are world class and address areas of medical need such as diabetes, metabolic syndrome and chronic pain. The support of the government and this grant will not only help Phosphagenics meet its key milestones, but also provides support for our local scientists, researchers and developers.' APPENDIX AND NOTES TO EDITORS About Phosphagenics Limited Phosphagenics is a Melbourne-based, globally driven biotechnology company focused on the discovery of new and cost effective ways to enhance the bioavailability, activity, safety and delivery of proven pharmaceutical and nutraceutical products. Phosphagenics' core technology is built around the science and application of phosphorylation, a process where the addition of a phosphate group has been found to enhance the bioavailability, activity and safety of existing pharmaceuticals and nutraceuticals, as well as to assist in the production of drug delivery platforms. Phosphagenics' shares are listed on the Australian Stock Exchange (POH) and the London Stock Exchange's Alternative Investment Market (PSG). An ADR - Level 1 program has been established in the US with the Bank of New York (PPGNY) for US investors to trade in Phosphagenics' stock on the 'over-the-counter' market. For more information, please visit Phosphagenics' web site at www.phosphagenics.co Company Contact Details: US Investor and Media Contacts: Dr Esra Ogru Mr Brian Ritchie Phosphagenics Limited Financial Dynamics Executive Vice President Research & Development +1 212 850 5683 +61 3 9605 5900 Mr Harry Rosen Phosphagenics Limited Managing Director +61 3 9605 5900 Safe Harbor Statement This press release contains forward-looking statements based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialise, actual results could vary materially from the Phosphagenics' expectations and projections. Risks and uncertainties include general industry conditions and competition; economic conditions, such as interest rate and currency exchange rate fluctuations; technological advances and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; domestic and foreign health care reforms and governmental laws and regulations. This information is provided by RNS The company news service from the London Stock Exchange MSCGCGDUGBGGGRX |
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
